NYSE · Healthcare
Edwards Lifesciences Corp (EW)
As-reported financials and recent SEC filings for Edwards Lifesciences Corp, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$6.07B
Net income
$1.07B
Net margin
17.7%
Diluted EPS
$1.83
ROE
10.4%
P/E (TTM)
46.0×
Market cap
$49.01B
Debt / equity
0.1×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2023 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B |
| Gross profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B |
| Operating income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B |
| Net income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B |
| Diluted EPS | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
32026-06-01
View on EDGAR →1442026-05-29
View on EDGAR →1442026-05-29
View on EDGAR →42026-05-29
View on EDGAR →1442026-05-27
View on EDGAR →42026-05-27
View on EDGAR →SD2026-05-27
View on EDGAR →1442026-05-22
View on EDGAR →Go deeper on EW
Search Edwards Lifesciences Corp’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.